Varda Space Industries company profile: valuation, funding & revenue

This Varda Space Industries company profile covers the company's valuation, revenue, funding rounds, investors and history. Varda Space Industries works in space, with a focus on in-space manufacturing. It was founded in 2020 and is headquartered in El Segundo, California, United States. Every figure links to a public source, and anything the company hasn't disclosed is marked as such.

Revenue

Funding history

Varda Space Industries timeline

Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.

• 2020 — Varda Space Industries is founded in El Segundo by Will Bruey (CEO) and Delian Asparouhov.
• Jul 2025 — Series C: US$187M. Investors: Natural Capital and Shrug Capital (leads); Peter Thiel, Lux Capital, Khosla Ventures, Caffeinated Capital.
• July 2025 — Total funding: About US$329 million after the Series C (as reported).

Investors

Overview

Varda Space Industries manufactures pharmaceuticals in orbit. Its small, automated capsules launch to low Earth orbit, process drug compounds in microgravity, and return to Earth under a heat shield, landing by parachute. Microgravity can allow some molecules, especially proteins and other complex drugs, to form crystals with different structures, sizes or purity than on Earth, which could improve how drugs are stored, dissolved or delivered. Varda has flown several missions and in July 2025 raised a US$187 million Series C to increase launch frequency, expand laboratory facilities and scale up work on biologics.

Will Bruey, the CEO, and Delian Asparouhov founded Varda in 2020. Bruey previously worked at SpaceX on spacecraft, including Dragon. Asparouhov is a partner at Founders Fund, which incubated the company. Varda is based in El Segundo, California, near other Los Angeles-area space companies.

Products and missions

• W-series capsules: reentry capsules that host manufacturing in orbit and bring products back to Earth.
• Orbital processing: automated equipment that crystallises drug compounds in microgravity.
• Hypersonic testing: each reentry also provides flight data at very high speeds, which is valuable to defense customers studying hypersonic flight.
• Laboratory services: ground-based research to identify drugs that could benefit from space processing.

Funding

Varda raised early funding led by Founders Fund and Lux Capital, then a Series B. In July 2025 it raised a US$187 million Series C led by Natural Capital and Shrug Capital, with Peter Thiel, Lux Capital, Khosla Ventures and Caffeinated Capital participating, according to CNBC, bringing total funding to about US$329 million. Varda didn't disclose a valuation, and third-party estimates conflict, so we show it as not disclosed.

Business model

Varda aims to earn revenue from pharmaceutical partners that pay for space processing of their compounds, potentially leading to licensing or royalties if improved drug forms reach the market. It also earns revenue from government customers, particularly the US Air Force Research Laboratory, which uses its capsules for hypersonic reentry testing. That defense revenue helps fund the company while the pharmaceutical business develops.

Competition

Varda competes with other in-space manufacturing and return companies, such as Space Forge in the UK and The Exploration Company in Europe, and with research on the International Space Station. On the pharmaceutical side, its competition is improved crystallisation techniques on Earth. Its strengths are flight experience, frequent missions and a combined pharma-defense model.

Varda at a glance

Varda Space Industries is an El Segundo, California, company founded in 2020 by former SpaceX engineer Will Bruey and Founders Fund partner Delian Asparouhov. It manufactures drug compounds in orbit using reentry capsules and provides hypersonic test data. It raised a US$187 million Series C in July 2025 led by Natural Capital and Shrug Capital, without disclosing a valuation.

Timeline

• 2020: founded with backing from Founders Fund.
• 2023: launches its first capsule, W-1, which processes the HIV drug ritonavir in orbit.
• 2024: W-1 lands in Utah after regulatory approvals for reentry; further missions follow.
• July 2025: raises a US$187 million Series C.

Why make drugs in space

On Earth, gravity causes sedimentation and convection as crystals form, which can affect their size and structure. In microgravity, molecules can arrange more evenly, sometimes producing crystals with different properties. For pharmaceuticals, crystal form influences stability, shelf life and how a drug dissolves in the body. Some research has suggested that space-grown crystals could help create formulations that are easier to administer, for example converting intravenous drugs into injections. The commercial question is whether those benefits are large enough to justify the cost of orbital processing.

Regulatory firsts

Varda's first capsule waited months in orbit before receiving permission to land, because returning a commercial capsule to US soil required approvals from the Federal Aviation Administration that had never been issued in that form before. The process highlighted how regulation needs to adapt for new space businesses. Later missions benefited from the precedent.

Who works with Varda

Varda's customers and partners include pharmaceutical companies, the US Air Force Research Laboratory and research institutions.

Risks

• Commercial proof: drugs made in space must show real advantages.
• Regulatory paths: both reentry approvals and drug regulators must be satisfied.
• Launch costs: economics depend on cheap, frequent launches.
• Defense dependence: early revenue relies on government testing contracts.

Questions for observers

• Which drug partners have signed commercial agreements?
• How often can Varda fly missions?
• What results have space-processed compounds shown?

Reentry as a service

Most satellites never come back to Earth, so very few companies have experience returning hardware safely from orbit. Varda's capsules must survive temperatures of thousands of degrees during reentry, slow down with parachutes and land in designated areas. Each successful return demonstrates a capability that is valuable beyond pharmaceuticals: returning samples, materials or hardware from orbit, and testing materials and sensors at hypersonic speeds. The US military has a strong interest in hypersonic flight, and real reentry data is expensive to obtain through other means. Varda's ability to fly frequent missions turns its capsules into a test platform as well as a factory, giving it a second market while pharmaceutical customers evaluate the benefits of space-made drugs.

Valuation context

Because Varda hasn't disclosed a valuation and third-party estimates disagree, we don't include it in valuation-ranked tables. Its total funding of about US$329 million shows strong investor commitment.

Who funds Varda

Varda's investors include Founders Fund, which incubated it, along with Lux Capital, Khosla Ventures and newer backers such as Natural Capital and Shrug Capital, which led the Series C. Peter Thiel also invested personally in the latest round.

Questions for drug developers

• Which properties of your compound could change in microgravity?
• What ground research is needed before a mission?

Latest developments (October 2026)

Varda flew its sixth W-Series capsule in 2026: W-6 launched on 30 March on SpaceX's Transporter-16 mission and landed at the Koonibba range in South Australia in May, according to the State Space Agency of Ukraine. The mission carried hypersonic test payloads for the US Air Force Research Laboratory. Varda has also reported a Series D of about US$251 million led by Lux Capital and Natural Capital, according to the Los Angeles Business Journal. See our space startups guide.

What to watch

Watch mission cadence, pharmaceutical partnerships and any disclosed valuation. Our guide to space startups covers related companies.

Takeaways

Drug developers may gain a new way to improve formulations. Founders can see how dual revenue streams can fund long-term science. Investors should note that its valuation hasn't been disclosed.

Sources

Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.

1. CNBC (via NBC New York)